Ziltivekimab's free IL-6 reduction quantified, aligning with hsCRP in cardiovascular trials

Measuring active interleukin-6 (IL-6) is challenging in patients treated with IL-6 ligand inhibitors like ziltivekimab, as conventional assays cannot differentiate free from bound IL-6. This poses a problem for monitoring therapeutic efficacy in cardiovascular disease trials where IL-6 inhibition is critical. Understanding the true reduction of biologically active IL-6 is essential for validating the drug's mechanism and interpreting downstream inflammatory markers like C-reactive protein (hsCRP).

Researchers developed a quantitative model based on a target-mediated drug disposition framework to predict free IL-6 concentrations over time. This model utilized data on total IL-6 and ziltivekimab concentrations following drug administration. Predicted free IL-6 levels were then compared against directly measured hsCRP levels from the RESCUE trial, an inflammatory biomarker known to be induced by IL-6.

The quantitative model estimated significant reductions in free IL-6 concentrations from baseline to week 12 in the RESCUE study. For patients treated with ziltivekimab 7.5 mg, estimated free IL-6 decreased by 72%. Higher doses yielded even greater reductions: 82% for 15 mg and 90% for 30 mg. These proportional predicted percent reductions in estimated free IL-6 closely matched the proportional reductions observed in directly measured hsCRP levels.

Estimated free IL-6 decreased immediately after the first dose, was dose-dependent, and mirrored the timing of hsCRP reduction. These findings support ziltivekimab's targeted anti-inflammatory effect through free IL-6 reduction.